DSM-6: What the APA's Roadmap Says, and Why There's No Release Date
Contenido del artículo
The short answer, because it is the thing everyone is actually searching for: there is no DSM-6 release date. The American Psychiatric Association has not announced one. The current standard remains DSM-5-TR, published in May 2022, and it will remain the standard for years.
What does exist is a roadmap. The APA announced it on 28 January 2026, and the lead paper from the Structure and Dimensions Subcommittee was published in the American Journal of Psychiatry in May 2026 (Öngür et al., 2026; PMID 41593835). The most widely cited outside estimate puts finalization "around the year 2030" (Kreisman, 2026). Treat that as an estimate, not a date. DSM-5 took roughly fourteen years from planning to publication.
So this is not news you need to act on this quarter. It is news worth reading carefully, because of what it proposes.
What the roadmap actually commits to
Four subcommittees are doing the work, and their titles are the clearest statement of intent available:
| Subcommittee | What it is examining |
|---|---|
| Structure and dimensions | Combining categorical diagnosis with severity measured on a spectrum |
| Functionality and quality of life | Whether functional outcomes belong inside the diagnostic framework |
| Socioeconomic, cultural and environmental determinants | Broadening the factors used to reach a diagnosis |
| Biomarkers | Integrating objective biological measures for the first time |
The proposed framework organizes assessment into four parts: contextual and social factors, biomarkers, severity-based diagnoses, and transdiagnostic features. And the stated ambition is to produce a living document — an online-centred resource that updates continuously rather than a static book every fifteen years.
Read that list again with a clinician's eye. Severity on a spectrum. Functional outcomes. Transdiagnostic features. Continuous revision.
That is a description of measurement-based care.
The manual is catching up to the practice
Clinicians already doing measurement-based care have been working dimensionally for years, because the categorical model does not survive contact with a caseload. A patient does not have depression or not-depression. They have a PHQ-9 of 19 that was 24 three weeks ago, and the direction of travel matters more than the threshold they happen to sit above today.
Transdiagnostic features are the same story. Emotional dysregulation, sleep disruption and rumination show up across diagnostic boundaries, which is why practices end up administering measures that cut across categories rather than one per diagnosis.
None of this is a prediction about DSM-6. It is an observation about what the roadmap is describing: the formalization of something practice arrived at first. If the next manual grades severity and tracks function, then a single categorical judgement at intake stops being sufficient documentation. Repeated measurement becomes the substrate diagnosis sits on, rather than an optional add-on for outcome reporting.
Where I would push back
An op-ed that only agrees is not worth writing. Three parts of this deserve skepticism.
The biomarker ambition has been promised before. NIMH launched the Research Domain Criteria framework in 2010 with a similar premise: move past descriptive symptom clusters toward measurable biology. Sixteen years later I am not aware of a biomarker in routine clinical use for any common mental disorder — no blood test for major depression, no imaging finding that adjudicates a bipolar diagnosis. That is an editorial judgement rather than a cited finding, and I would be glad to be corrected on it. The science may well arrive. But "for the first time the DSM will use biology" is a statement of intent, and intent has a poor track record here. A subcommittee cannot will a biomarker into existence.
A living document creates problems nobody has costed. Continuous revision is obviously better for scientific accuracy. It is genuinely hard for everything downstream. Payers adjudicate claims against fixed criteria. Medico-legal documentation is assessed against the standard in force at the time of the encounter. Training programmes, licensing exams and every piece of clinical software encode a snapshot. If criteria can change quarterly, each of those needs a versioning story, and the roadmap does not supply one. "Which version of the criteria did you diagnose under" is a question the field is not currently equipped to answer.
Broadening the factors used to determine diagnosis cuts both ways. Including socioeconomic, cultural and environmental determinants is right — context changes what a symptom means. It also widens clinical discretion, and wider discretion without tighter measurement is how you get diagnostic drift and inequity. The determinants work and the dimensions work have to ship together, or the first makes the second harder.
When is DSM-6 coming out?
No date has been set. What is known:
- DSM-5-TR (May 2022) is the current standard and remains the basis for diagnosis, documentation and billing.
- The roadmap was published 28 January 2026 as a set of proposals, not as draft criteria.
- Outside estimates cluster around 2029–2030. These are estimates from commentators, not APA commitments.
- A named successor may not even be called DSM-6. If the manual becomes a continuously updated resource, edition numbering is part of what changes.
Be skeptical of any page giving you a confident release date. Several of the pages ranking for this question right now still carry dates that have already passed.
What this means for practice, concretely
Nothing urgent. But two things are worth deciding early, because they are cheap now and expensive later.
Do not buy tooling that hard-codes DSM-5-TR. If the direction of travel is dimensional severity, transdiagnostic measures and continuously revised criteria, then software with diagnostic criteria compiled into it is a liability with a known expiry date. Ask any vendor how criteria are updated, who updates them, and what happens to historical records when a definition changes.
Start collecting longitudinal severity data now, whatever the manual says. If DSM-6 grades severity and function, practices with three years of repeated measurement will be able to describe their patients in the new vocabulary immediately. Practices with categorical intake notes will be starting over. That is true regardless of whether the 2030 estimate holds, and it is true even if DSM-6 never ships, because the clinical value of longitudinal measurement does not depend on a manual endorsing it.
For the current framework, our DSM-5-TR clinical guide covers the diagnostic categories, severity specifiers and the ICD crosswalk as they stand today. That is what you diagnose under now, and for some years yet.
Sources
- American Psychiatric Association. APA Releases Roadmap for the Future of the DSM. 28 January 2026.
- Öngür D, Abi-Dargham A, Clarke DE, et al. The Future of DSM: A Report From the Structure and Dimensions Subcommittee. American Journal of Psychiatry, May 2026. PMID 41593835.
- Kreisman JJ. What You Can Expect in the DSM-6. Psychology Today, 18 February 2026.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). 2022.
- Insel T, Cuthbert B, Garvey M, et al. Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. American Journal of Psychiatry, 2010;167(7):748-751. PMID 20595427.